Researchers and oncologists are excited to learn that mRNA vaccines can not only elicit neutralizing antibodies, commonly regarded as a key correlate of protection against SARS-CoV-2 infection, but also induce CD8+ T cell responses that mediate early protection against the virus and help surveil and eradicate tumor reservoirs in cancer patients (5). The gene discussed is CD8A; the disease is cancer.